• Naomi Pearce, Emily Bristow

Pearce IP BioBlast: w/e 09 October 2020

Significant biosimilar activities this week include:

  • 05 Oct 20: Medicure announced it has entered a License, Manufacture and Supply Agreement with Reliance Life Sciences for a cardiovascular biosimilar product for EU, US and Canada. Medicure is responsible for the regulatory approval process for that product.

  • 06 Oct 20: Onco'Zine reported a new study released by the American Society of Clinical Oncology Quality Care Symposium indicates that Sandoz's Zarxio® (biosimilar filgrastim) is not only safe and effective, but is cost effective in treating chemotherapy-induced febrile neutropenia in early-stage breast cancer patients.

  • 06 Oct 20, EU: Samsung Bioepis and Biogen announced the European Medicines Agency has accepted for review its Marketing Authorisation Application for SB11 (proposed ranibizumab biosimilar).

  • 08 Oct 20: Korea Biomedical Review reported Celltrion has received approval for Ph III trials of CT-P39 (proposed omalizumab biosimilar).

Biosimilars Bulletin 
Search by tags

© 2019 Pearce IP | Australia

  • LinkedIn Social Icon